Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus vs MMF in SPK Transplantation
NCT00140543Phase 3Completed
- Sponsor
- EUROSPK Study Group
- Start
- Feb 2002
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of sirolimus in graft rejection (2 arms), sponsored by EUROSPK Study Group. Primary endpoint: Incidence of biopsy-proven (kidney) rejection episodes at 1 year. Started Feb 2002; status: completed.
02
Drugs
sirolimus
03
Conditions
graft rejection
Beyond the preview
Go deeper on NCT00140543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00140543.